Get the Stockscreener App
0.0001
99.40%
-0.0167
Vaxxinity Inc stock is traded at $0.0001, with a volume of 576.
It is down -99.40% in the last 24 hours and down -99.40% over the past month.
See More
Previous Close:
$0.0168
Open:
$0.01
24h Volume:
576
Relative Volume:
8.99
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-56.94M
P/E Ratio:
-0.000222
EPS:
-0.4502
Net Cash Flow:
$-58.04M
1W Performance:
-99.40%
1M Performance:
-99.40%
6M Performance:
-95.00%
1Y Performance:
-97.29%
1-Day Range:
$0.0001
$0.01
1-Week Range:
$0.0001
$0.01
52-Week Range:
$0.0001
$0.0168
Vaxxinity Inc Stock (VAXX) Company Profile
Compare VAXX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VAXX
Vaxxinity Inc
|
0.0001 | 0 | 0 | -56.94M | -58.04M | -0.4502 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxxinity Inc Stock (VAXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-23 | Initiated | Robert W. Baird | Outperform |
| Apr-27-22 | Initiated | Evercore ISI | In-line |
Vaxxinity Inc Stock (VAXX) Latest News
Vaxxinity (VAXX) Stock Trends and Sentiment 2026 - MarketBeat
Vaxxinity, Inc. Revenue Breakdown – OTC:VAXX - TradingView
If You Invested $1,000 in Vaxxinity, Inc. (VAXX) - Stock Titan
Price to sales forward of Vaxxinity, Inc. – OTC:VAXX - TradingView
Vaxxinity (VAXX) Insider Trading Activity 2026 - MarketBeat
Vaxxinity Inc Class A Actuals & Estimates (OTC:VAXX) - TradingView
Number of shareholders of Vaxxinity, Inc. – OTC:VAXX - TradingView
Vaxxinity Inc stock (US92239B1035): focus on vaccine pipeline after recent financing update - AD HOC NEWS
Vaxxinity Inc stock (US92239B1035): Trading at historic low amid biotech challenges - AD HOC NEWS
VAXX Stock Crashes 99.5% on NASDAQ: Vaxxinity Inc. Hits Record Low - Meyka
MAHA ACTION WELCOMES BIOTECH PIONEER LOU REESE TO ITS BOARD OF DIRECTORS - Yahoo Finance
Why Is Vaxxinity, Inc. (VAXX) Stock Down Today? - Meyka
Vaxxinity, Inc.Class A Common Stock (Nasdaq:VAXX) Stock Quote - The Chronicle-Journal
Vaxxinity Inc Stock: Pioneering Synthetic Vaccines in a Competitive Biotech Landscape for North Amer - AD HOC NEWS
VAXX (Vaxxinity) NASDAQ $0.0001 pre-market 27 Mar 2026: Top loser, clinical risk - Meyka
Vaxxinity Inc stock faces Nasdaq delisting risk amid biotech funding crunch - ad-hoc-news.de
VAXX (Vaxxinity, NASDAQ) at $0.0075 on 19 Mar 2026: Earnings could change momentum - Meyka
Vaxxinity Inc Stock (ISIN: US92239B1035) Faces Uncertainty Amid Biotech Sector Headwinds - AD HOC NEWS
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders - Meyka
VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook - Meyka
Dallas District Court Split in High-Stakes Stock Dispute - Inforney News
Top 6 Healthcare Stock Picks in 2025 - timothysykes.com
VAXX Stock Price, News & Analysis - Stock Titan
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity, Inc. (VAXX) stock historical prices and data - Yahoo Finance Australia
Vaxxinity - The Pharma Letter
A Potential Parkinson’s Treatment Has Promising Results - Time Magazine
Parkinson's Prevention May Include Tetanus Vaccination - Walgreens
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial - Nature
AZTR Stock Price and Chart — AMEX:AZTR - TradingView
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
VAXX Stock Price and Chart — OTC:VAXX - TradingView
Vaxxinity Inc Cl A (VAXX) Stock Price and News - The Globe and Mail
Vaxxinity, Inc. Financial Statements – OTC:VAXX - TradingView
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
5/3/24 jj’s Watchlist. 🚨🚨🚨 - Moomoo
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - TradingView
Vaxxinity Issues Shareholder Letter - Yahoo Finance
Vaxxinity | 10-K: FY2023 Annual Report - Moomoo
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity reports breakthrough in Parkinson's treatment By Investing.com - Investing.com UK
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV
Lou Reese Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Vaxxinity is brewing up meds for a spacefaring future - Pharma Voice
Vaxxinity, UCF to develop special new vaccines for deep-space astronauts - The Business Journals
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - GlobeNewswire
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity Inc Stock (VAXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
1.21%
Cap:
|
Volume (24h):